Oncology Drug Report - Adcetris - Brentuximab Vedotin - 2011-2015 analysis; 2016-2021 Expectations

  • ID: 3973381
  • Report
  • Region: Global
  • 75 Pages
  • Cancer Research Analytics
1 of 5
All Details from Brand Name, Date of Approvals, Mechanism of Action, Molecular Structure and Route of Administration

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • Celgene
  • Emcure Pharmaceuticals
  • Medivation
  • Ono Pharmaceutical
  • Roche
  • MORE

“Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations” is a comprehensive report on the first and only approved drug of Seattle Genetics called Adcetris, which is also the first drug approved by the USFDA for classical Hodgkin’s Lymphoma (cHL) in 34 years (1977-2011). It was launched in 2011 in the US for Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma (sALCL). It is designed through Seattle Genetics’ proprietary asset ‘ADC Technology’ and falls under the targeted therapy group. It is the second-approved drug based on ADC technology.

The report gives an analysis of the historical annual sales (from 2011-2015), historical quarterly sales (Q1-2012 to Q3-2016) and sales expectations (from 2016-2021). The drug falls under the CD30 antibody-drug conjugate (ADC), class of drugs. It is currently marketed in 65 countries across the world.

The report gives the basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about the drug, litigations, number of clinical trials (by year and by phase), and so on.

Details of the sales analysis section:

Historical annual sales analysis: Historical annual sales have been analysed in USD and JPY terms with the help of graphical representation of sales over 2011-2015. The report has all the data in tabular format as well. We have highlighted key reason for the sales trend in all the geographies listed. It also includes cumulative sales mapping since its launch until Q3-2016.

Historical quarterly sales analysis: Additionally, we have sales analysis on quarterly basis for the last 19 quarters from Q1-2012 to Q3-2016. The quarterly data is also in graphical as well as tabular format. Specifically, we have also included update for Q3-2016.

Expected sales analysis: The report has our expectations for sales of Adcetris over 2016-2021. We have highlighted key reasons for our expectations. All the historical as well as expected sales analysis is based on:

  • Total global sales
  • US and Canada sales
  • International sales
    • Europe sales
    • Japan sales
    • Emerging markets sales

Other important details
Clinical study details: We have included recently-released key clinical study results for trials, which compare Adcetris with other chemo-agents. The report also includes clinical trial results of key drugs in cHL and CTCL.

List of competing drugs: Additionally, all the drugs which compete/can compete with Adcetris in its different markets such as cHL, CTCL, PTCL, etc. are listed with their details including brand name, API, company, class of drug, therapy class and treatment preference.

Key event tracker: The report highlights key events that have taken place for Adcetris from 2011 to November 2016. It gives additional information about which key events have driven sales for the drug over this period.

Clinical trials numbers: The report provides numbers of clinical trials, which have started for Adcetris in 2016, 2015 and 2014 and for different phases: phase III, phase III/II and phase II.

Generics filings: Votrient will go off-patent in the first half of the next decade. We have provided information on two companies that have filed DMFs, but we do not expect the generics to be launched until the drug’s expiry.

News: We have listed news related to Adcetris that would impact the drug’s performance.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • Celgene
  • Emcure Pharmaceuticals
  • Medivation
  • Ono Pharmaceutical
  • Roche
  • MORE

1. Basic Information
1.1 Brand name/multiple brand names (US, Europe, Japan, RoW)
1.2 Research code
1.3 API
1.4 Molecular weight
1.5 Molecular structure
1.6 Immuno-oncology status
1.7 Broader indications
1.8 Therapy class
1.9 Class of drug
1.10 Companies involved in marketing (US, Europe, Japan, RoW)
1.11 Innovation-related information
1.12 First approval dates (US, Europe, Japan)
1.13 Patent expiry dates (US and Europe)
1.14 Molecule type
1.15 Dosage form/strength
1.16 Route of administration
1.17 Global sales-2015/2016E (USD, bn)
1.18 Mechanism of action
1.19 Pharmacodynamic properties
1.20 Pharmacokinetic properties
1.21 Co-promotion agreement
1.21 Royalty-related information
1.22 About the drug

2. Approval timeline infographic (2011-2016)

3. Regulatory approval details (US, Europe, Japan and RoW)
3.1 Approval table
3.2 Drug approvals in RoW countries

4. Historical annual sales analysis (2011-2016E)
4.1 Total sales (USD)
4.2 Sales mix - US and Canada/international
4.3 US and Canada sales (USD)
4.4 International sales (USD, JPY)
4.5 Europe sales(USD, JPY)
4.6 Japan sales(USD, JPY)
4.7 Emerging markets sales(USD, JPY)
4.8 Historical annual sales table (USD, JPY)

5. Historical quarterly sales analysis (Q1-2012 to Q3-2016)
5.1 Total sales (USD)
5.2 Sales mix - US and Canada/international
5.3 US and Canada sales (USD)
5.4 International sales (USD, JPY)
5.5 Europe sales(USD, JPY)
5.6 Japan sales(USD, JPY)
5.7 Emerging markets sales(USD, JPY)
5.8 Historical quarterly sales table (USD, JPY)

6. Historical cumulative sales (2011 to Q3-2016)
6.1 Total sales (USD)
6.2 US and Canada sales (USD)
6.3 International sales (USD)
6.4 Europe sales(USD)
6.5 Japan sales(USD)
6.6 Emerging markets sales(USD)
6.7 Cumulative sales table (USD)

7. Q3-2016 update
7.1 Q3-2015 to Q3-2016 quarterly total sales (USD)
7.2 Q3-2015 to Q3-2016 quarterly US and Canada sales (USD)
7.3 Q3-2015 to Q3-2016 quarterly international sales (USD)
7.4 Q3-2015 to Q3-2016 quarterly Europe sales (USD)
7.5 Q3-2015 to Q3-2016 quarterly Japan sales (USD)
7.5 Q3-2015 to Q3-2016 quarterly emerging markets sales (USD)
7.6 Q3-2015 to Q3-2016 cumulative sales table (USD)

8. Sales expectations (2016E-2021E)
8.1 Total sales (USD)
8.2 Sales mix - US and Canada/international
8.3 US and Canada sales (USD)
8.4 International sales (USD, JPY)
8.5 Europe sales(USD, JPY)
8.6 Japan sales(USD, JPY)
8.7 Emerging markets sales(USD, JPY)
8.8 Historical quarterly sales table (USD, JPY)

9. Clinical study of ALCANZA trial

10. List of key drugs used for the treatment of Hodgkin's and non-Hodgkin's lymphoma
10.1 For Hodgkin's lymphoma
10.2 For CTCL
10.3 For DLBCL
10.4 For PTCL
10.5 Combination regimens for different types of lymphomas

11. Clinical study results for the drug approved for Hodgkin's lymphoma (cHL)
11.1 Adcetris/brentuximab vedotin
11.2 Opdivo/nivolumab

12. Clinical study results for the drug approved for cutaneous T-cell lymphoma (CTCL)
12.1 Istodax/romidepsin
12.2 Zolinza/vorinostat
12.3 Poteligeo/mogamulizumab
12.4 Targretin/bexarotene
12.5 Valchlor/mechlorethamine (gel)
12.6 Ontak/denileukin diftitox

13. Event tracker

14. Clinical trials of Adcetris (US)
14.1 Year-wise (2014, 2015 and 2016)
14.2 Phase-wise (II, II/III, III)

15. Litigations related to Adcetris

16. News around Adcetris (including 25 press releases)

17. Annexure
17.1 Drug coverage list of 251 drugs
17.2 Methodology
17.3 Disclaimer

List of Exhibits

Exhibit 1: Approval infographic
Exhibit 2: Drug approvals table across the three major geographies
Exhibit 3: Drug approvals in RoW countries
Exhibit 4: Historical annual total sales in USD mn
Exhibit 5: Historical annual sales mix - US and Canada/international
Exhibit 6: Historical annual US and Canada sales in USD mn
Exhibit 7: Historical annual international sales in USD mn
Exhibit 8: Historical annual international sales in JPY mn
Exhibit 9: Historical annual Europe sales in USD mn
Exhibit 10: Historical annual Europe sales in JPY mn
Exhibit 11: Historical annual Japan sales in USD mn
Exhibit 12: Historical annual Japan sales in JPY mn
Exhibit 13: Historical annual emerging markets sales in USD mn
Exhibit 14: Historical annual emerging markets sales in JPY mn
Exhibit 15: Historical annual sales table in USD mn
Exhibit 16: Average exchange rates in USD/JPY
Exhibit 17: Historical annual sales table in JPY bn
Exhibit 18: Historical quarterly total sales in USD mn
Exhibit 19: Historical quarterly sales mix - US and Canada/international
Exhibit 20: Historical quarterly US and Canada sales in USD mn
Exhibit 21: Historical quarterly international sales in USD mn
Exhibit 22: Historical quarterly international sales in JPY mn
Exhibit 23: Historical quarterly Europe sales in USD mn
Exhibit 24: Historical quarterly Europe sales in JPY mn
Exhibit 25: Historical quarterly Japan sales in USD mn
Exhibit 26: Historical quarterly Japan sales in JPY mn
Exhibit 27: Historical quarterly emerging markets sales in USD mn
Exhibit 28: Historical quarterly emerging markets sales in JPY mn
Exhibit 29: Historical quarterly sales table in USD mn
Exhibit 30: Average exchange rates in USD/JPY
Exhibit 31: Historical quarterly sales table in JPY bn
Exhibit 32: Historical cumulative annual total sales in USD mn
Exhibit 33: Historical cumulative annual US and Canada sales in USD mn
Exhibit 34: Historical cumulative annual international sales in USD mn
Exhibit 35: Historical cumulative annual Europe sales in USD mn
Exhibit 36: Historical cumulative annual Japan sales in USD mn
Exhibit 37: Historical cumulative annual emerging markets sales in USD mn
Exhibit 38: Historical cumulative annual sales table in USD mn
Exhibit 39: Q3-2015 to Q3-2016 total sales in USD mn
Exhibit 40: Q3-2015 to Q3-2016 US and Canada sales in USD mn
Exhibit 41: Q3-2015 to Q3-2016 international sales in USD mn
Exhibit 42: Q3-2015 to Q3-2016 Europe sales in USD mn
Exhibit 43: Q3-2015 to Q3-2016 Japan sales in USD mn
Exhibit 44: Q3-2015 to Q3-2016 emerging markets sales in USD mn
Exhibit 45: Q3-2015 to Q3-2016 sales table in USD mn
Exhibit 46: Expected annual total sales in USD mn
Exhibit 47: Expected annual sales mix - US and Canada/international
Exhibit 48: Expected annual US and Canada sales in USD mn
Exhibit 49: Expected annual international sales in USD mn
Exhibit 50: Expected annual international sales in USD mn
Exhibit 51: Expected annual Europe sales in USD mn
Exhibit 52: Expected annual Europe sales in JPY mn
Exhibit 53: Expected annual Japan sales in USD mn
Exhibit 54: Expected annual Japan sales in JPY mn
Exhibit 55: Expected annual emerging markets sales in USD mn
Exhibit 56: Expected annual emerging markets sales in JPY mn
Exhibit 57: Expected annual sales table in USD mn
Exhibit 58: Expected annual sales table in JPY mn
Exhibit 59: ALCANZA study results for Adcetris
Exhibit 60: List of the key drugs used for the treatment of Hodgkin's lymphoma
Exhibit 61: List of the key drugs used for the treatment of cutaneous T-cell lymphoma (CTCL)
Exhibit 62: List of the key drugs used for the treatment of diffuse large B-cell lymphoma (DLBCL)
Exhibit 63: List of the key drugs used for the treatment of peripheral T-cell lymphoma (PTCL)
Exhibit 64: List of the combination regimens used for different types of lymphomas
Exhibit 65: Basis of drugs approved for Hodgkin's lymphoma
Exhibit 66: Efficacy results for the approval of Adcetris for Hodgkin's lymphoma
Exhibit 67: Efficacy results for the approval of Opdivo for Hodgkin's lymphoma
Exhibit 68: Basis of drugs approved for cutaneous T-cell lymphoma (CTCL)
Exhibit 69: Efficacy results for the approval of Istodax for CTCL
Exhibit 70: Efficacy results for the approval of Zolinza for CTCL (study-1)
Exhibit 71: Efficacy results for the approval of Zolinza for CTCL (study-2)
Exhibit 72: Efficacy results for the approval of Poteligeo for CTCL
Exhibit 73: Efficacy results for the approval of Targretin for CTCL
Exhibit 74: Efficacy results for the approval of Valchlor for CTCL
Exhibit 75: Efficacy results for the approval of Ontak for CTCL (study-1)
Exhibit 76: Efficacy results for the approval of Ontak for CTCL (study-2)
Exhibit 77: Event tracker mapping the major event related to Adcetris
Exhibit 78: Year-wise clinical trials in US (2016)
Exhibit 79: Year-wise clinical trials in US (2015)
Exhibit 80: Year-wise clinical trials in US (2014)
Exhibit 81: Table for year-wise clinical trials in US (2016)
Exhibit 82: Table for year-wise clinical trials in US (2015)
Exhibit 83: Table for year-wise clinical trials in US (2014)
Exhibit 84: Phase-wise clinical trials in US (phase III)
Exhibit 85: Phase-wise clinical trials in US (phase II/III)
Exhibit 86: Phase-wise clinical trials in US (phase II)
Exhibit 87: Table for phase-wise clinical trials in US (phase III)
Exhibit 88: Table for phase-wise clinical trials in US (phase II/III)
Exhibit 89: Table for phase-wise clinical trials in US (phase II)
Exhibit 90: Key events summary-covering news related to Adcetris

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Accredo Speciality Pharmacy
  • Actelion Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb (BMS)
  • CTI Biopharma
  • Celgene
  • Eisai Pharmaceuticals
  • Emcure Pharmaceuticals
  • Kyowa Hakko Kirin
  • MedImmune
  • Medivation
  • Merck & Company
  • Merck KGaA
  • Ono Pharmaceutical
  • Otsuka Pharmaceutical
  • Pfizer
  • Roche
  • Seattle Genetics
  • Spectrum pharmaceuticals
  • Takeda Pharmaceuticals
  • Valeant Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll